Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Van Raemdonck, Geert A A ^a   Tjalma, Wiebren A A ^b   Coen, Edmond P ^a   Depuydt, Christophe E ^c   Van Ostade, Xaveer W M ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Algemeen Medisch Laboratorium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 4; PYRUVATE KINASE; PYRUVATE KINASE ISOZYME M1; PYRUVATE KINASE ISOZYME M2; TUMOR MARKER; UNCLASSIFIED DRUG; ACTININ; ACTN4 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BODY FLUID; CERVICOVAGINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEOMICS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRAL CLEARANCE; LONGITUDINAL STUDY; METABOLISM; PAPILLOMAVIRIDAE; PHYSIOLOGY; PRECANCER; REPRODUCIBILITY; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA; VIROLOGY;

ACTININ; AGED; BODY FLUIDS; CERVIX UTERI; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PRECANCEROUS CONDITIONS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINA;

EID: 84933055854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106488     Document Type: Article

References (47)

1. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006) HPV-mediated cervical carcinogenesis: Concepts and clinical implications. J Pathol 208: 152-164. 10.1002/path.1866 [doi].
2. Sjoeborg KD, Trope A, Lie AK, Jonassen CM, Steinbakk M, et al. (2010) HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol 118: 29-34. S0090-8258(10)00257-X [pii];10.1016/j.ygyno.2010.03.007 [doi].
3. Paavonen J (2007) Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 11 Suppl 2: S3-S9. S1201-9712(07)60015-0 [pii];10.1016/S1201-9712(07)60015-0 [doi].
4. Maglennon GA, McIntosh P, Doorbar J (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414: 153-163. S0042-6822(11)00144-9 [pii];10.1016/j.virol.2011.03.019 [doi].
5. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer 7: 11-22. nrc2050 [pii];10.1038/nrc2050 [doi].
6. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, et al. (2002) Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 325: 572.
7. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, et al. (2009) Clinician's guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect Dis 9: 347-356. S1473-3099(09)70108-2 [pii];10.1016/S1473-3099(09)70108-2 [doi].
8. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, et al. (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-383. djq562 [pii];10.1093/jnci/djq562 [doi].
9. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, et al CJ (2010) HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: Cohort study. BMJ 340: C1040.
10. Bradford L, Goodman A (2013) Cervical cancer screening and prevention in low-resource settings. Clin Obstet Gynecol 56: 76-87. 10.1097/GRF.0b013e31828237ac [doi].
11. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, et al. (2010) Human papillomavirus infection and reinfection in adult women: The role of sexual activity and natural immunity. Cancer Res 70: 8569-8577. 0008-5472.CAN-10-0621 [pii];10.1158/0008-5472.CAN-10-0621 [doi].
12. Crosignani P, De SA, Fara GM, Isidori AM, Lenzi A, et al. (2013) Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health 13: 642. 1471-2458-13-642 [pii];10.1186/1471-2458-13-642 [doi].
13. Zhu X, Lv J, Yu L, Zhu X, Wu J, et al. (2009) Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol 112: 248-256. S0090-8258(08)00809-3 [pii];10.1016/j.ygyno.2008.09.045 [doi].
14. Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, et al. (2005) Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol 99: 26-35. S0090-8258(05)00390-2 [pii];10.1016/j.ygyno.2005.05.041 [doi].
15. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, et al. (2004) Protein profiling of cervical cancer by protein-biochips: Proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211: 227-234. 10.1016/j.canlet.2004.02.014 [doi];S0304383504001673 [pii].
16. Choi YP, Kang S, Hong S, Xie X, Cho NH (2005) Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 5: 1481-1493. 10.1002/pmic.200401021 [doi].
17. Uleberg KE, Munk AC, Skaland I, Furlan C, Van Diermen B, et al. (2011) A protein profile study to discriminate CIN lesions from normal cervical epithelium. Cell Oncol (Dordr). 10.1007/s13402-011-0047-3 [doi].
18. Arnouk H, Merkley MA, Podolsky RH, Stoppler H, Santos C, et al. (2009) Characterization of Molecular Markers Indicative of Cervical Cancer Progression. Proteomics Clin Appl 3: 516-527. 10.1002/prca.200800068 [doi].
19. Lomnytska MI, Becker S, Hellman K, Hellstrom AC, Souchelnytskyi S, et al. (2010) Diagnostic protein marker patterns in squamous cervical cancer. Proteomics Clin Appl 4: 17-31. 10.1002/prca.200900086 [doi].
20. Lee KA, Kang JW, Shim JH, Kho CW, Park SG, et al. (2005) Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics. Gynecol Oncol 99: 142-152. S0090-8258(05)00411-7 [pii];10.1016/j.ygyno.2005.05.039 [doi].
21. Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, et al. (2007) Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the future. J Proteome Res 6: 4549-4555. 10.1021/pr070529w [doi].
22. Lin YW, Lai HC, Lin CY, Chiou JY, Shui HA, et al. (2006) Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. Int J Gynecol Cancer 16: 1216-1224. IJG583 [pii];10.1111/j.1525-1438.2006.00583.x [doi].
23. Guo X, Abliz G, Reyimu H, Zhao F, Kadeer N, et al. (2012) The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: A 2D liquid-phase chromatography/mass spectrometry study. Biomarkers 17: 352-361. 10.3109/1354750X.2012.673133 [doi].
24. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, et al. (2006) High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 44: 2518-2523. 44/7/2518 [pii];10.1128/JCM.02440-05 [doi].
25. Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW (2009) Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci 7: 17. 1477-5956-7-17 [pii];10.1186/1477-5956-7-17 [doi].
26. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, et al. (2007) Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 11: 881-891. JCMM073 [pii];10.1111/j.1582-4934.2007.00073.x [doi].
27. Depuydt CE, Criel AM, Benoy IH, ArbynM, Vereecken AJ, et al. (2012) Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 16: 3096-3104. 10.1111/j.1582-4934.2012.01631.x [doi].
28. Zegels G, Van Raemdonck GA, Tjalma WA, Van Ostade XW (2010) Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci 8: 63. 1477-5956-8-63 [pii];10.1186/1477-5956-8-63 [doi].
29. Yamakawa K, Yoshida K, Nishikawa H, Kato T, Iwamoto T (2007) Comparative analysis of interindividual variations in the seminal plasma proteome of fertile men with identification of potential markers for azoospermia in infertile patients. J Androl 28: 858-865. jandrol.107.002824 [pii];10.2164/jandrol.107.002824 [doi].
30. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.
31. Gadducci A, Tana R, Cosio S, Genazzani AR (2008) The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature. Crit Rev Oncol Hematol 66: 10-20. S1040-8428(07)00183-7 [pii];10.1016/j.critrevonc.2007.09.002 [doi].
32. Nakatsuji H, Nishimura N, Yamamura R, Kanayama HO, Sasaki T (2008) Involvement of actinin-4 in the recruitment of JRAB/MICAL-L2 to cell-cell junctions and the formation of functional tight junctions. Mol Cell Biol 28: 3324-3335. MCB.00144-08 [pii];10.1128/MCB.00144-08 [doi].
33. Barbolina MV, Adley BP, Kelly DL, Fought AJ, Scholtens DM, et al. (2008) Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest 88: 602-614. labinvest200825 [pii];10.1038/labinvest.2008.25 [doi].
34. Khurana S, Chakraborty S, Cheng X, Su YT, Kao HY (2011) The actinbinding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells. J Biol Chem 286: 1850-1859. M110.162107 [pii];10.1074/jbc.M110.162107 [doi].
35. Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, et al. (2009) Actinin-4 gene amplification in ovarian cancer: A candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 22: 499-507. modpathol2008234 [pii];10.1038/modpathol.2008.234 [doi].
36. Yamamoto S, Tsuda H, Honda K, TakanoM, Tamai S, et al. (2012) ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology 60: 1073-1083. 10.1111/j.1365-2559.2011.04163.x [doi].
37. Yamada S, Yanamoto S, Yoshida H, Yoshitomi I, Kawasaki G, et al. (2010) RNAi-mediated down-regulation of alpha-actinin-4 decreases invasion potential in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 39: 61-67. S0901-5027(09)01125-4 [pii];10.1016/j.ijom.2009.10.003 [doi].
38. Foley KS, Young PW (2013) An analysis of splicing, actin-binding properties, heterodimerization and molecular interactions of the non-muscle alpha-actinins. Biochem J 452: 477-488. BJ20121824 [pii];10.1042/BJ20121824 [doi].
39. Khurana S, Chakraborty S, Zhao X, Liu Y, Guan D, et al. (2012) Identification of a novel LXXLL motif in alpha-actinin 4-spliced isoform that is critical for its interaction with estrogen receptor alpha and co-activators. J Biol Chem 287: 35418-35429. M112.401364 [pii];10.1074/jbc.M112.401364 [doi].
40. Chung SH, Franceschi S, Lambert PF (2010) Estrogen and ERalpha: Culprits in cervical cancer? Trends Endocrinol Metab 21: 504-511. S1043-2760(10)00062-7 [pii];10.1016/j.tem.2010.03.005 [doi].
41. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233. nature06734 [pii];10.1038/nature06734 [doi].
42. Mazurek S (2007) Pyruvate kinase type M2: A key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 99-124.
43. Parker CE, Borchers CH (2014) Mass spectrometry based biomarker discovery, verification, and validation -Quality assurance and control of protein biomarker assays. Mol Oncol 8: 840-858. S1574-7891(14)00054-4 [pii];10.1016/j.molonc.2014.03.006 [doi].
44. Bodily J, Laimins LA (2011) Persistence of human papillomavirus infection: Keys to malignant progression. Trends Microbiol 19: 33-39. S0966-842X(10)00177-0 [pii];10.1016/j.tim.2010.10.002 [doi].
45. Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109: S15-S21. S0090-8258(08)00105-4 [pii];10.1016/j.ygyno.2008.02.003 [doi].
46. Cerigo H, Coutlee F, Franco EL, Brassard P (2012) Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. J Med Screen 19: 42-48. 19/1/42 [pii];10.1258/jms.2012.012011 [doi].
47. Dzuba IG, Diaz EY, Allen B, Leonard YF, Lazcano Ponce EC, et al. (2002) The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 11: 265-275. 10.1089/152460902753668466 [doi].